 DEER PARK, Ill., Feb. 08, 2021 GLOBE NEWSWIRE -- Eton Pharmaceuticals, Inc. Nasdaq: ETON, a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has sold its neurology portfolio to Azurity Pharmaceuticals. The portfolio includes Etons lamotrigine ET-105, zonisamide ET-104, and topiramate ET-101 product candidates, which have all been submitted to the U.S. Food and Drug Administration as new drug applications and are currently under review by the agency. 